Merck Ranks #7 Analyst Pick in the Dow as Blue Chips Slip

Merck is the #7 analyst pick among the 30 stocks in the Dow Jones Industrial Average and ranks above the median analyst pick in the S&P 500, according to a tally of major brokerage opinions published September 1, 2026; MRK last traded at 148.85, up 0.74%, while the Dow 30 ETF fell 0.73%.

Merck sits seventh on the analyst-preference table for the 30 companies in the Dow Jones Industrial Average, according to a tally of ratings from the major brokerage houses reported by Nasdaq Markets. The same exercise places the drugmaker above the median analyst pick across the far wider S&P 500 membership.

Seventh out of 30 puts Merck (MRK) inside the top quarter of the index by aggregate sell-side enthusiasm. That is a ranking, not a forecast, and it is worth being precise about what it measures: brokerage ratings, converted to a numeric scale and averaged, then sorted. It tells you where the analyst community is leaning relative to the other 29 Dow constituents on the day the tally was struck. It does not tell you the stock is cheap, and it does not tell you what the next quarter's numbers will look like.

What the tape did while the ranking landed

The market backdrop on September 1 was mildly risk-off. As of the last trade at 16:31:13 GMT, the SPDR S&P 500 ETF (SPY) was at $762.02, down 0.66% from a prior close of $767.05, with a day range of $761.17 to $764.67 — the close-to-low proximity telling you sellers had the afternoon. The Invesco QQQ Trust (QQQ), the Nasdaq 100 proxy, was weaker still at $708.31, off 1.18%. The SPDR Dow Jones Industrial Average ETF (DIA) was at $527.71, down 0.73%, having spent the session between $527.62 and $531.65.

Merck bucked it. MRK last traded at 148.85, up 0.74% from a prior close of 147.76. Against a Dow tracker down 0.73%, that is roughly 1.5 percentage points of relative outperformance on the day — an illustrative gap derived from the two quoted moves, not a reported figure. On a day when the growth-heavy Nasdaq 100 proxy was the worst of the three benchmarks and the broad market drifted toward its lows, a large-cap pharmaceutical name finishing green is the textbook defensive rotation signature.

The intraday detail is less flattering than the headline gain. Merck's session range ran from 148.63 to 151.68, and the last trade of 148.85 sits within a whisker of the low. On an illustrative basis, the last price is about 1.9% below the session high. In other words, the stock was materially stronger earlier in the day and gave most of that back as the broader indexes slid into the close. A green print on a red tape still counts, but the shape of the day says buyers were not chasing.

Why a defensive pharma name rises up the rankings

Analyst-preference tables tend to reward two things that healthcare majors are structurally good at supplying: earnings visibility and a rating floor. When a stock's forward revenue is underpinned by patent-protected products with contracted pricing and inelastic demand, sell-side analysts are less likely to carry a sell rating on it, and more likely to sit at buy or overweight with modest conviction. That pushes the average rating up mechanically, even in the absence of a specific catalyst.

That is also the honest caveat on any top-10-of-30 ranking. A composite rating score is a measure of consensus positioning, and consensus positioning is a lagging variable. It has already been priced by definition — the analysts publishing those ratings are the same people whose research the market has read. The information value in the ranking is comparative rather than predictive: it tells you which Dow names the sell side would defend in a drawdown, which is a different question from which ones will outperform.

What makes the second data point in the tally more interesting is its scope. Ranking above the S&P 500 median means Merck screens better than half of a 500-stock universe that includes hundreds of smaller, faster-growing, more thinly covered companies — the cohort where enthusiastic single-analyst buy ratings usually inflate composite scores. Clearing the median from inside the mega-cap bracket, where coverage is deep and skepticism is well funded, is a slightly harder test than the raw number suggests.

Where this leaves the Dow's healthcare weighting

The Dow is price-weighted, which means a constituent's influence on the index is a function of its share price rather than its market capitalization. At 148.85, Merck sits in the middle of the Dow's price distribution — it is neither one of the index's dominant movers nor a rounding error. A 0.74% day in MRK does not rescue an index whose tracker fell 0.73%, and it did not: DIA closed nearer its low than its high.

The wider read on September 1 is a familiar one for anyone watching 2026's rotation dynamics. The Nasdaq 100 proxy fell almost twice as much as the S&P 500 proxy, and the Dow tracker landed between the two. That is the signature of a session in which high-multiple technology took the brunt and lower-beta, dividend-paying industrials, staples and healthcare cushioned. Merck was on the right side of that split.

What to watch from here

Three things determine whether the seventh-place ranking has any staying power.

• Rating migration, not rating level. A composite score matters less than its direction. Upgrades or downgrades from the larger coverage houses move the average; reiterations do not. Watch for changes in the distribution — a single sell initiation from a heavyweight can reshuffle the Dow table faster than three neutral-to-buy moves.
• Whether the defensive bid persists. Merck's outperformance on the day is only meaningful if the rotation that produced it holds. If the Nasdaq 100's underperformance reverses, the relative advantage that pushed MRK green while DIA fell disappears with it.
• The gap between the session high and the last trade. Closing near 148.63 after trading as high as 151.68 is the kind of intraday fade that repeats if there is a supply of sellers at the top of the range. Sustained trade above the prior close of 147.76 is the simple technical marker; failure to hold it turns a strong ranking into a stock that is being sold into strength.

None of that changes the underlying point of the tally. On a day when the broad American benchmarks were down and the technology-heavy one was down hardest, the sell side's seventh-favorite Dow stock was one of the names holding its ground. That is what a defensive holding is supposed to do, and it is the clearest justification for the ranking that the tape offered.

All prices in this article are as of the last trade at 16:31:13 GMT on September 1, 2026, with the market open and quotes intraday.

Key facts

• MRK last trade: 148.85, +0.74% (as of 16:31:13 GMT, Sept 1, 2026)
• Dow analyst ranking: #7 of the 30 Dow Jones Industrial Average constituents
• S&P 500 comparison: Ranks above the median analyst pick among S&P 500 components
• Benchmarks on the day: DIA $527.71 (-0.73%), SPY $762.02 (-0.66%), QQQ $708.31 (-1.18%)

Frequently asked questions

Where does Merck rank among Dow stocks by analyst opinion?

Merck is the #7 analyst pick among the 30 companies in the Dow Jones Industrial Average, based on a tally of ratings from the major brokerage houses reported on September 1, 2026. The same exercise also places Merck above the median analyst pick among the components of the broader S&P 500 index.

How did MRK trade on the day the ranking was published?

MRK last traded at 148.85, up 0.74% from a prior close of 147.76, as of 16:31:13 GMT on September 1, 2026. Its session range ran from 148.63 to 151.68, meaning the last print sat close to the day's low after the stock gave back most of an earlier intraday gain.

Did Merck outperform the Dow that session?

Yes. The SPDR Dow Jones Industrial Average ETF (DIA) was at $527.71, down 0.73% on the day, while MRK rose 0.74%. That works out to roughly 1.5 percentage points of relative outperformance on an illustrative basis, derived from the two quoted daily moves rather than reported as a separate figure.

What does an analyst ranking like this actually measure?

It converts published brokerage ratings into a numeric scale, averages them across the covering analysts, and sorts the resulting scores. It is a measure of where the sell side is leaning relative to peers on a given date. It is not a valuation signal, an earnings forecast, or a prediction of future returns.

How did the major US benchmarks perform that day?

All three were lower. The S&P 500 proxy SPY closed at $762.02, off 0.66%; the Dow 30 proxy DIA was at $527.71, down 0.73%; and the Nasdaq 100 proxy QQQ was weakest at $708.31, down 1.18%. The pattern is consistent with a session in which higher-multiple technology took the heaviest selling.

Why do healthcare majors often score well on consensus rating screens?

Large pharmaceutical companies typically offer earnings visibility from patent-protected products with relatively inelastic demand, which makes analysts less likely to publish outright sell ratings. Fewer negative ratings lifts the average score mechanically, so a high composite ranking can reflect defensive characteristics rather than any specific near-term catalyst.

Sources

• Dow Analyst Moves: MRK — Nasdaq Markets

Photo: Castorly Stock · Pexels Licence — source